scholarly journals A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic MoleculesJ.Am.Chem.Soc.1995,117, 5179−5197

1996 ◽  
Vol 118 (9) ◽  
pp. 2309-2309 ◽  
Author(s):  
Wendy D. Cornell ◽  
Piotr Cieplak ◽  
Christopher I. Bayly ◽  
Ian R. Gould ◽  
Kenneth M. Merz ◽  
...  
1995 ◽  
Vol 117 (19) ◽  
pp. 5179-5197 ◽  
Author(s):  
Wendy D. Cornell ◽  
Piotr Cieplak ◽  
Christopher I. Bayly ◽  
Ian R. Gould ◽  
Kenneth M. Merz ◽  
...  

2001 ◽  
Vol 537 (1-3) ◽  
pp. 283-305 ◽  
Author(s):  
D Bosch ◽  
N Foloppe ◽  
N Pastor ◽  
L Pardo ◽  
M Campillo

2013 ◽  
Vol 31 (sup1) ◽  
pp. 70-70 ◽  
Author(s):  
Marie Zgarbová ◽  
Michal Otyepka ◽  
Pavel Banáš ◽  
F. Javier Luque ◽  
Thomas E. Cheatham ◽  
...  

2011 ◽  
Vol 7 (9) ◽  
pp. 2886-2902 ◽  
Author(s):  
Marie Zgarbová ◽  
Michal Otyepka ◽  
Jiří Šponer ◽  
Arnošt Mládek ◽  
Pavel Banáš ◽  
...  

Author(s):  
Alfonso Soler-Bistué ◽  
Angeles Zorreguieta ◽  
Marcelo E. Tolmasky

Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, led to the design of nucleotide analogs that when being part of these oligomers enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs are the first-generation bridge nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second generation BNA, BNANC (2'-O,4'-aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but in some cases also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds were researched, the results are very promising warranting more efforts in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future offering great hope to oligonucleotide-based fields of research and applications.


Molecules ◽  
2019 ◽  
Vol 24 (12) ◽  
pp. 2297 ◽  
Author(s):  
Alfonso Soler-Bistué ◽  
Angeles Zorreguieta ◽  
Marcelo E. Tolmasky

Oligonucleotides are key compounds widely used for research, diagnostics, and therapeutics. The rapid increase in oligonucleotide-based applications, together with the progress in nucleic acids research, has led to the design of nucleotide analogs that, when part of these oligomers, enhance their efficiency, bioavailability, or stability. One of the most useful nucleotide analogs is the first-generation bridged nucleic acids (BNA), also known as locked nucleic acids (LNA), which were used in combination with ribonucleotides, deoxyribonucleotides, or other analogs to construct oligomers with diverse applications. However, there is still room to improve their efficiency, bioavailability, stability, and, importantly, toxicity. A second-generation BNA, BNANC (2′-O,4′-aminoethylene bridged nucleic acid), has been recently made available. Oligomers containing these analogs not only showed less toxicity when compared to LNA-containing compounds but, in some cases, also exhibited higher specificity. Although there are still few applications where BNANC-containing compounds have been researched, the promising results warrant more effort in incorporating these analogs for other applications. Furthermore, newer BNA compounds will be introduced in the near future, offering great hope to oligonucleotide-based fields of research and applications.


Sign in / Sign up

Export Citation Format

Share Document